Medication dosing in outpatients with heart failure after implementation of a practice-based performance improvement intervention: Findings from IMPROVE HF

Congestive Heart Failure

Volumn 18, Issue 1, 2012, Pages 9-17

  Gheorghiade, Mihai ^a   Albert, Nancy M ^b   Curtis, Anne B ^c   Thomas Heywood, J ^d   McBride, Mark L ^e   Inge, Patches Johnson ^e   Mehra, Mandeep R ^f   O'Connor, Christopher M ^g   Reynolds, Dwight ^h   Walsh, Mary Norine ⁱ   Yancy, Clyde W ^a   Fonarow, Gregg C ^j  

^a NORTHWESTERN UNIVERSITY   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

^c UNIVERSITY AT BUFFALO   (United States)

^d SCRIPPS CLINIC   (United States)

^e Outcome Sciences Inc   (United States)

^f UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^g DUKE UNIVERSITY MEDICAL CENTER   (United States)

^h UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

ⁱ St Vincent Heart Center of Indiana   (United States)

^j UCLA MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BISOPROLOL; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL SUCCINATE; METOPROLOL TARTRATE; SODIUM;

ADULT; AGE; AGED; ARTICLE; CLINICAL PRACTICE; EDEMA; FEMALE; FOLLOW UP; HEART FAILURE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; NEGRO; OUTPATIENT; PATIENT EDUCATION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SODIUM BLOOD LEVEL; SYSTOLIC BLOOD PRESSURE; TREATMENT RESPONSE;

ADRENERGIC BETA-ANTAGONISTS; AGED; ALDOSTERONE ANTAGONISTS; AMBULATORY CARE; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; EVIDENCE-BASED MEDICINE; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; OUTPATIENTS; PHYSICIAN'S PRACTICE PATTERNS; PROSPECTIVE STUDIES; QUALITY ASSURANCE, HEALTH CARE; REGISTRIES; UNITED STATES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84856260028     PISSN: 15275299     EISSN: 17517133     Source Type: Journal    
DOI: 10.1111/j.1751-7133.2011.00250.x     Document Type: Article

References (24)

1. Lloyd-Jones D, Adams RJ, Brown TM, et al. Heart disease and stroke statistics - 2010 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation. 2010;121:e46-e215.
2. National Heart, Lung, and Blood Institute, National Institutes of Health. Morbidity and mortality: 2009 chart book on cardiovascular, lung, and blood diseases. Accessed July 7, 2010.
3. Loehr LR, Rosamond WD, Chang PP, et al. Heart failure incidence and survival (from the Atherosclerosis Risk in Communities study). Am J Cardiol. 2008;101:1016-1022.
4. Schappert SM, Rechsteiner EA. Ambulatory medical care utilization estimates for 2006. Natl Health Stat Rep. 2008;8:1-29.
5. SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293-302.
6. Cohn JN, Johnson G, Ziesche S, et al. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303-310.
7. Cohn JN, Tognoni G; Valsartan Heart Failure Trial Investigators. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667-1675.
8. Jong P, Yusuf S, Rousseau MF, et al. Effect of enalapril on 12-year survival and life expectancy in patients with left ventricular systolic dysfunction: a follow-up study. Lancet. 2003;361:1843-1848.
9. Young JB, Dunlap ME, Pfeffer MA, et al. Mortality and morbidity reduction with candesartan in patients with chronic heart failure and left ventricular systolic dysfunction: results of the CHARM low-left ventricular ejection fraction trials. Circulation. 2004;110:2618-2626.
10. Califf RM, Lokhnygina Y, Velazquez EJ, et al. Usefulness of β blockers in high-risk patients after myocardial infarction in conjunction with captopril and/or valsartan (from the VALsartan In Acute Myocardial Infarction [VALIANT] trial). Am J Cardiol. 2009;104:151-157.
11. Hunt SA, Abraham WT, Chin MH, et al. ACC/AHA 2005 guideline update for the diagnosis and management of chronic heart failure in the adult: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Update the 2001 Guidelines for the Evaluation and Management of Heart Failure): developed in collaboration with the American College of Chest Physicians and the International Society for Heart and Lung Transplantation; endorsed by the Heart Rhythm Society. Circulation. 2005;112:e154-e235.
12. Jessup M, Abraham WT, Casey DE, et al. 2009 focused update: ACCF/AHA guidelines for the diagnosis and management of heart failure in adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the International Society for Heart and Lung Transplantation. Circulation. 2009;119:1977-2016.
13. Komajda M, Follath F, Swedberg K, et al. The EuroHeart Failure Survey programme - a survey on the quality of care among patients with heart failure in Europe. Part 2: treatment. Eur Heart J. 2003;24:464-474.
14. Fowler MB, Lottes SR, Nelson JJ, et al. β-blocker dosing in community-based treatment of heart failure. Am Heart J. 2007;153:1029-1036.
15. Heywood JT, Fonarow GC, Yancy CW, et al. Comparison of medical therapy dosing in outpatients cared for in cardiology practices with heart failure and reduced ejection fraction with and without device therapy: report from IMPROVE HF. Circ Heart Fail. 2010;3:596-605.
16. Fonarow GC, Yancy CW, Albert NM, et al. Improving the use of evidence-based heart failure therapies in the outpatient setting: the IMPROVE HF performance improvement registry. Am Heart J. 2007;154:12-38.
17. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100:2312-2318.
18. Konstam MA, Neaton JD, Dickstein K, et al. Effects of high-dose versus low-dose losartan on clinical outcomes in patients with heart failure (HEAAL study): a randomized, double-blind trial. Lancet. 2009;374:1840-1848.
19. Bristow MR, Gilbert EM, Abraham WT, et al. Carvedilol produces dose-related improvements in left ventricular function and survival in subjects with chronic heart failure. Circulation. 1996;94:2807-2816.
20. Bozkurt B, Agoston I, Knowlton AA. Complications of inappropriate use of spironolactone in heart failure: when an old medicine spirals out of new guidelines. J Am Coll Cardiol. 2003;41:211-214.
21. Svensson M, Gustafsson F, Galatius S, et al. How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure? J Card Fail. 2004;10:297-303.
22. Whellan DJ, Gaulden L, Gattis WA, et al. The benefit of implementing a heart failure disease management program. Arch Intern Med. 2001;161:2223-2228.
23. Ansari M, Shlipak MG, Heidenreich PA, et al. Improving guideline adherence, a randomized trial evaluating strategies to increase β-blocker use in heart failure. Circulation. 2003;107:2799-2804.
24. Moyer-Knox D, Mueller TM, Vuckovic K, et al. Remote titration of carvedilol for heart failure patients by advanced practice nurses. J Card Fail. 2004;10:225-227.